This website is intended for UK patients who have been prescribed Calquence (acalabrutinib) only. For UK members of the public, please visit http://www.astrazeneca.co.uk/

This does not replace the Patient Information Leaflet, which can be found in the carton containing your medicine and should be read alongside this information.

MyCLL logo, link to the MyCLL homepage
MyCLL logo, link to the MyCLL homepage
  • Home
  • Understanding CLL
  • About Calquence
  • Managing my CLL
  • Resources
  • FAQs
calquence logoastrazeneca logo
 
MyCLL logo, link to the MyCLL homepage
  • Home
  • Understanding CLL
  • About Calquence
  • Managing my CLL
  • Resources
  • FAQs
Hero – calquence
Hero Mob – calquence

Frequently Asked Questions (FAQs)

fixed nav trigger

Taking my medicine
Side effects and safety
Appointments and monitoring
Everyday life
Taking my medicine
Side effects and safety
Appointments and monitoring
Everyday life

Find answers to the most commonly asked questions about CLL and Calquence below


Taking my medicine

Your medicine is an oral targeted treatment that helps fight CLL cancer cells, offering an alternative to traditional chemotherapy.1,2 For more information, visit About Calquence.

If you have taken more Calquence than instructed, see a doctor or go to the nearest hospital immediately. Take the tablets and patient information leaflet with you.1,2  For more information on how to take your medicine, visit our About Calquence page.

Calquence is a targeted cancer treatment that blocks a signal inside CLL cells, called bruton tyrosine kinase or BTK. This signal normally tells CLL cells to survive and grow. By blocking BTK, Calquence switches off these signals. This can slow down the growth and build-up of CLL cells in the lymph nodes (small glands in your body).1

 

Venetoclax is another targeted treatment that blocks a protein in CLL cells called BCL-2. This protein helps CLL cells stay alive when they should naturally break down. By blocking BCL-2, venetoclax makes it easier for CLL cells to die.3

 

Using both medicines together helps stop CLL cells from growing in two different ways. These medicines are both tablets you take by mouth. They are targeted treatments and not chemotherapy. For more information on these medicines, read the packaging leaflets in each box and speak to your healthcare team.

 

Always take Calquence exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.

Most people continue treatment until the medicine stops controlling the CLL or side effects outweigh the benefits. Some patients remain on Calquence for several years with regular monitoring. If you are prescribed acalabrutinib in combination with venetoclax, this will be given for a maximum of 14 treatment cycles (each cycle is 28 days).1 Your doctor will review your response at every appointment and guide any future changes.

This medicinal product does not require any special storage conditions.1 For more information, please read the patient information leaflet.

When you start venetoclax, your doctor will slowly increase your dose to help your body adjust. This is to lower the chance of a problem called tumour lysis syndrome (TLS), which can happen when cancer cells die quickly.3 To reduce this risk, you may need extra blood tests and to drink plenty of fluids. Your team will tell you exactly what to do and when to come in. If you feel unwell at any time during the ramp up of venetoclax, contact your healthcare team straight away.

Side effects and safety

This is not a full list and you may have other side effects. Please read the package leaflets in each box and talk to your healthcare team. In some cases, your doctor may need to stop your treatment. Some side effects require urgent care. See the patient information leaflet and About Calquence page for more information.

 

Colds, throat, chest infections

  • Wash your hands often with soap and water
  • Wear a mask in crowded places
  • Tell your doctor straight away if you have any signs of infection. This could be a fever, chills, or flu-like symptoms

 

Stomach upset

  • Drink fluids and try small, simple meals (for example: toast, rice, bananas, soup)
  • Avoid alcohol, live yoghurt, greasy or spicy foods and raw fruits and vegetables
  • Do gentle exercise like short walks, if you feel able

 

Urinary tract infections (UTIs)

  • Rest and drink plenty of fluids
  • Try to avoid drinks that can irritate your bladder, like juice, coffee, and alcohol
  • Wipe from front to back when you go to the toilet
  • Keep the genital area clean and dry

 

Bruising and bleeding

  • Use a soft toothbrush
  • Take care with sharp objects
  • Wear shoes indoors to protect your feet

 

Feeling very tired (fatigue)

  • Take short naps during the day (about 30 minutes)
  • Drink plenty of water to stay hydrated
  • Do gentle exercise, like walking or stretching

 

Muscle and joint pain

  • Ask your team about pain relief and physiotherapy
  • Do gentle exercises following the advice of your physiotherapist

 

Headache

  • Rest and keep hydrated
  • A cup of tea or coffee may help

 

Rash

  • Avoid skincare products with alcohol, as these can make your skin sore
  • Talk to your doctor or nurse, as they can give you creams or medicine to help

 

Contact your healthcare team about any side effects and new or worsening symptoms. If you are unsure about how to take your treatment, ask your healthcare team as they will support you with any questions you may have.

Back
to top

Appointments and monitoring

You will have regular blood tests and check‑ups to check how you are doing and how well this medicine is working for you.

If your symptoms are improving since taking Calquence, it suggests your medication may be working for you. You should continue taking your medication until you are advised otherwise by your healthcare professional.1,2

Managing chronic lymphocytic leukaemia (CLL) is a team effort. You’ll be supported by a team of doctors, nurses and other specialists who will help you to manage your treatment. You could use an appointment checklist to help you make the most of the time you have with your healthcare team. Tell your doctor, nurse, or pharmacist about all medicines you are taking, have recently taken or might take including vitamins and herbal remedies. Talk to your healthcare team about any new side effects or worsening symptoms. It can also help to talk about how you are feeling day-to-day. This includes any changes to your wellbeing or quality of life. 

Everyday life

Tell your doctor, nurse, or pharmacist about all medicines you are taking, have recently taken or might take. This includes vitamins and herbal remedies. Some medicines (like certain antibiotics, antifungals, or St John’s wort) can change how your treatment works.1 Calquence may make you bleed more easily.2 Tell your doctor if you take medicines that can increase bleeding. This includes medicines like aspirin, clopidogrel, or blood thinners. Please refer to the patient information leaflet for more information.

Talk to your doctor before taking Calquence if you have recently had surgery or dental work or are about to. Your doctor may tell you to stop taking Calquence for a short time.1

Other supportive sources include CLL Support, Blood Cancer UK, Macmillan Cancer Support, Leukaemia Care, and the NHS website. You can access the patient information leaflet for more information on your medicine here. Your clinical nurse specialist can connect you with peer-support services to help you live well with CLL.5

Back
to top

Looking for resources to support you?

View resources

Abbreviations:

BCL-2, B-cell lymphoma 2; BTK, bruton tyrosine kinase; CLL, chronic lymphocytic leukaemia

References:

  1. Calquence 100 mg tablets. Patient Information Leaflet. Available at: https://www.medicines.org.uk/emc/product/14853/pil (Accessed November 2026).
  2. Calquence (acalabrutinib) 100 mg film-coated tablet SmPC.
  3. Venetoclax. Patient Information Leaflet. Available at: https://www.medicines.org.uk/emc/files/pil.10476.pdf (Accessed November 2026).
  4. Leukaemia Care. Active monitoring for CLL. Available at: https://www.leukaemiacare.org.uk/about-leukaemia/types/chronic-lymphocytic-leukaemia-cll/active-monitoring-for-cll/ (Accessed November 2026).
  5. Live well with CLL. CLL support (2019). Available from https://images.cllsupport.org.uk/wp-content/uploads/2020/01/31110716/BOOKLET-FINAL-PROOF..pdf (Accessed November 2026).
  6. Macmillan. Infection. Available at: https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/infection (Accessed November 2026). 
  7. NHS. Urinary tract infections (UTIs). Available at: https://www.nhs.uk/conditions/urinary-tract-infections-utis/ (Accessed November 2026).
  8. Macmillan. Tiredness (fatigue). Available at: https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/tiredness (Accessed November 2026).
  9. O’Brien S.M. et al. Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice. Front Oncol. 2021; 11:720704.
  10. Macmillan. Nausea and vomiting. Available at: https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/nausea-andvomiting (Accessed November 2026).
  11. National Cancer Institute. Nausea and Vomiting and Cancer Treatment - Side Effects. Available at: https://www.cancer.gov/about-cancer/treatment/side-effects/nausea. (Accessed November 2026).
  12. National Cancer Institute. Bleeding and bruising (thrombocytopenia) and cancer treatment. Available at: https://www.cancer.gov/about-cancer/treatment/sideeffects/bleeding-bruising (Accessed November 2026).
  13. Macmillan. Pain. Available at: https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/pain (Accessed November 2026).
  14. Macmillan. Cancer pain management without drugs. Available at: https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/pain/pain-management-without-drugs (Accessed November 2026).
  15. Macmillan. Skin and nail changes from cancer treatment. Available at: https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/changes-to-your-appearance-and-body-image/skin-and-nail-changes-from-cancer-treatment (Accessed November 2026). 

GB-82674 | November 2026

If you have any questions about your treatment, talk to your healthcare team or refer to the Patient Information Leaflet. All patient images are for illustrative purposes only.

Reporting side effects

If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in the Patient Information Leaflet. You can also report side effects directly via the Yellow Card Scheme, website: http://yellowcard.mhra.gov.uk/. By reporting side effects you can help provide more information on the safety of medicines.

Side effects can also be reported to AstraZeneca in the following ways:

Online: https://contactazmedical.astrazeneca.com

Email: Medical.InformationUK@astrazeneca.com

calquence logo

GB-80574 | November 2026

Privacy Notice Terms and Conditions Cookie Policy Contact Us
astrazeneca logo

Welcome to MyCLL

This website is intended only for UK patients who have been prescribed Calquence (acalabrutinib). This website has been produced and funded by AstraZeneca.

 

Please select the relevant option:

I am not a UK Calquence patient >